Movers and SHAKERS
Dyadic International (DYAI)
Could 2019 be transformational?
- R&D Advancement. The company continues to make progression in establishing C1 expression production and the purification process in multiple projects. The Schmallenberg virus (SBV) as part of the ZAPI project exceeded the intended expression levels (17x), and is potentially the first to enter in human trials. We believe glycan engineering intended in 2019 could be transformational for the company.
- Corporate Updates. The proof of concept collaborations totaled nine projects, including two newly added agreements with large pharmaceuticals in Q1 2019. Dyadic continues to validate C1's potential in biologic manufacturing, guiding an $8-$10 million burn rate this year. However, business development efforts are ongo...
Get full report on Channelchek desktop.
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.